 Daré Bioscience, Inc.DARE, a leader in womens health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group on May 5, 2020. During the panel discussion, Ms. Johnson will share insights from the Companys DARE-BV1 development program. DARE-BV1, a novel thermosetting bio-adhesive hydrogel formulated with clindamycin phosphate 2, is an investigational product for the treatment of bacterial vaginosis BV, one of the most common vaginal infections. 